Physician Assistant Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Smith

Physician Assistant Boise, ID Physician Assistant

NPI 1013905793 CMS profile 449195

7979 W Rifleman St, Boise, ID 83704

Open in the dashboard

General payments

$7,670

201 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Smith of Boise, ID is reported in the CMS Open Payments database as having received $7,670 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,575 71
2024 General $2,163 61
2023 General $991 41
2022 General $1,537 19
2021 General $380 8
2019 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Smith
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Jeffrey Smith were reported at $2,575. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Jeffrey Smith Physician Assistant median Middle half National median
2019 $23 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $380 $132 $37–$438 $132
2022 $1,537 $155 $48–$522 $149
2023 $991 $167 $52–$557 $160
2024 $2,163 $178 $55–$600 $164
2025 $2,575 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $5,508 171 payments
  2. Zimmer Biomet Holdings, Inc. $1,199 15 payments
  3. Medtronic, Inc. $579 6 payments
  4. Smith+Nephew, Inc. $182 2 payments
  5. Ethicon US, LLC $118 3 payments
  6. Pacira Pharmaceuticals Incorporated $50 2 payments
  7. Ferring Pharmaceuticals Inc. $34 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,915 193 payments
  2. Travel and Lodging $755 8 payments
Products named General payments · program years 2019–2025
  1. MAKO $2,361 58 payments
  2. INSIGNIA $1,470 51 payments
  3. Avenir $803 10 payments
  4. TRIDENT $604 27 payments
  5. TRIATHLON $458 9 payments
  6. TRITANIUM $350 14 payments
  7. AQUAMANTYS(TM) $244 3 payments
  8. RESTORATION $228 4 payments
  9. PLASMABLADE(TM) $208 2 payments
  10. X3 $150 1 payment
  11. Other $1,139 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

1,986

Median for Physician Assistant: 241

Drug cost

$25,409

Median for Physician Assistant: $4,110

Branded share of claims

2.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 32 $13,689
Doxycycline Hyclate Generic 134 $1,726
Tranexamic Acid Generic 206 $1,603
Gabapentin Generic 218 $1,503
Ondansetron Hcl Generic 207 $1,498
Tramadol Hcl Generic 329 $1,436
Meloxicam Generic 206 $1,104
Cyclobenzaprine Hcl Generic 155 $865
Montelukast Sodium Generic 91 $839
Oxycodone Hcl Generic 185 $552

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$61,670

Of which drugs: $13,340

Medicare patients

278

Average age 74

Services billed

1,530

157 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 63%
Depression 21%
Osteoporosis 20%
Diabetes 18%
Ischemic heart disease 18%
Chronic kidney disease 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 20 30 $12,061
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 561 $416

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record